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a b s t r a c t
Background: Photodynamic therapy (PDT) is a new modality in the treatment of cancer. This
study thus aims to examine whether the PDT is effective against in vivo hepatocellular
carcinoma.
Methods: In vivo efﬁcacy of PDT on hepatocellular carcinoma was tested in xenografted mice
with human hepatocellular carcinoma cell lines (Huh7) by utilizing a gold nanoparticles
(GNPs) conjugate of new photosensitizer (PS), purpurin-18-N-butylimide-N-methyl-D-
glucamine (Pu-18-N-butylimide-NMGA). The conjugate (PS-GNPs) was synthesized from the
reaction between Pu-18-N-butylimide-NMGA and chloroauric acid (HAuCl4). Mice were arbi-
trarily assigned into one of three groups. First group received saline alone, second group
received PS-GNPs alone, and the last group received both PS-GNPs and irradiation. PS-GNPs
was injected directly into the tumor mass and irradiations were performed 24hours after
injection of PS-GNPs.
Results: Tumor volume was signiﬁcantly smaller in the group which received both PS-GNPs
and irradiation compared with other two groups. Western blot and terminal deoxynu-
cleotidyl transferase dUTP nick end labeling (TUNEL) assay revealed that the group which
received both PS-GNPs and irradiation showed larger amount of apoptotic protein and DNA
fragmentation compared with other two groups.Conclusion: This study suggests that Pu-18-N-butylimide-NMGA-GNP conjugate is an effec-
tive agent for PDT in the treatment of hepatocellular carcinoma.
© 2013 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access∗ Corresponding author. National Research Laboratory for Mitochondri
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. Introduction
iver cancer is the sixth most common malignancy world-
ide and it constitutes about 5.7% of new cases. The prognosis
s so poor that number of cases (626,000) is almost same
s that of deaths (598,000).1 Therefore, it ranks the third in
otal number of deaths from cancer and the survival rate
anges between 3 and 5%.1 Majority of liver cancer is hep-
tocellular carcinoma which originates from hepatocytes.2
epatocellular carcinoma has also very poor survival rate for
ts incidence as well as other types of liver cancer, which
eans medical treatment is not so successful in improving
he survival rate of patients. So far the most effective treat-
ent to improve survival rate is surgical excision plus liver
ransplantation.2 Although surgical excision is a choice of
reatment for higher survival rate, accompanying conditions
uch as hepatic cirrhosis, vascular inﬁltration, and extrahep-
tic metastasislimit indication of surgery lower than 20% of
atients.2 Liver transplantation was known to improve the
urvival rate but ﬁnding a donor is not easy al all.2 As an
djunctive therapy, chemotherapy or radiotherapy has been
mployed. However, those adjunctive therapies inadvertently
ause toxicity or adverse reactions limiting long-term treat-
ent. In order to overcome those limitations, the PDT, a new
romising treatment modality, was recently developed.3 PDT
enerates singlet oxygen to selectively destroy target carci-
oma cells by a combination of visible light, photosensitizer
PS), and oxygen.4 Although PDT is not currently employed in
linical treatment of hepatocellular carcinoma, it is expected
o improve survival rate and quality of life without adverse
eactions or side effects commonly seen in chemotherapy or
adiotherapy.5 This study thus aims to examine whether the
DT is effective against in vivo hepatocellular carcinoma.
. Method
.1. Materials
eagents used to synthesize PS-gold nanoparticles (PS-GNPs)
ncluding methylene chloride (MC), methanol (MeOH), and
iethyl ether acetone were purchased from SK chemical
Korea). All other reagents including potassium hydroxide
KOH), 1-propanol, N-methyl-D-glucamine (NMGA), tetrahy-
rofuran (THF), and chloroauric acid were purchased from
igma-Aldrich and used without further puriﬁcation. 6-weeks
ld BALB/c-nu slc mice (female) were used for xenograft. The
DT was carried out using a diode laser generator apparatus
BioSpec LED, Russia) equipped witha halogen lamp, a band-
ass ﬁlter (640-710nm).
.2. Synthesis of photosensitizing agent
.2.1. Methyl Pheophorbide-a (MPa) from spirulina paciﬁc
lgae
00g of dried spirulina is dissolved in 2 L of acetone and stirred
t room temperature for two hours under nitrogen atmo-
phere in dark. Supernatants are ﬁltered more than twice and
cetone is removed by evaporation. 400mL of 5% sulfuric acid
nd 7,600mL of methanol are then added and kept overnight.ma 107
It is further puriﬁed by extraction of organic phase using
CH2Cl2 and water. Silica gel is added to the organic phase
to yield chlorophyll-a. Silica gel column chromatography is
ﬁnally used to extract pure MPa from chlorophyll-a.
2.2.2. Purpurin-18 (Pu-18)
2g of MPa is dissolved in a mixture solution composed of
800mL diethyl ether, 80mL KOH, and 24mL 1-propanol. 30mL
of pyridine is added to the solution to be stirred for 1∼3hours
under air atmosphere at room temperature. pH is adjusted to
2∼4 by using 10% sulfuric acid. 400mL of solution contain-
ing THF and MC with a ratio of 3:1 is added to separate organic
phase and dried to yield residue. Silica gel column chromatog-
raphy is ﬁnally used to extract pure Pu-18.
2.2.3. Pu-18-N-butylimide
Pu-18 is dissolved in 50mL of toluene and 10 molar N-
butylamine is added to be stirred for 24hours under nitrogen
in dark. Silica gel chromatography is used to extract pure
purpurin-18-N-butylimide.
2.2.4. N-methyl-D-glucamine (NMGA) salt of
Pu-18-N-butylimide(Pu-18-N-butylimide-NMGA)
Pu-18-N-butylimide and NMGA are under reaction for 4hours.
20m ﬁlter paper is then used to collect Pu-18-NMGA dis-
solved in aqueous phase.
2.2.5. Synthesis of PS-GNPs conjugate
A seed solution is prepared by allowing 5mL of PS (0.002M) to
reactwith 2.5mLofHAuCl4 (0.001M) at roomtemperature. The
seed solution is heated until its color turns into dark brown
and kept at room temperature. A mixture solution contain-
ing 25mL of PS (0.002M), 25mL of HAuCl4 (0.001M), and 1mL
of AgNO3 (0.005M) is prepared and 100L of seed solution is
added. The reaction mixture is centrifuged at 10,000 rpm for
10min and resuspended in water.
2.3. Cell culture
Human hepatocellular carcinoma cell line, Huh7 cells were
obtained from the Korean Cell Line Bank (Seoul, Korea) and
cultured in Dulbecco’s Modiﬁed Eagle’s medium (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(Sigma) and 1% penicillin/streptomycin (Lonza, USA) at 37 ◦C
in a humidiﬁed atmosphere of 5% CO2.
2.4. Xenograft studies
2.4.1. Cells injection
Animal studies were approved by the committee of the Inje
University. Two x 106 Huh7 cells per mouse were injected sub-
cutaneously into the right ﬂanks of 6-week-old female nude
mice. The mice were incubated to form a tumor mass (50-
100mm3) for 4 days. After tumor formation, 18 mice were ran-
domly assigned into one of 3 groups (6mice/group) to examine
whether the new modality of treatment is effective against
hepatocellular carcinoma. The treatment group received pho-
toirradiation after local injection of PS-GNPs into the tumor
mass (PS-GNPs plus irradiation group). The control group was
further divided into two groups: one received no particular
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Table 1 – Change in tumor size during 28 days after ﬁrst measurement of tumor mass (unit: mm3).
Groups Day 0 Day 4 Day 8 (ﬁrst
irradiation)
Day 12 Day 16 Day 20 Day 24 (second
irradiation)
Day 28
Saline alone 232.81 448.06 1,447.06 3,090.30 3,393.55 4,635.60 4,616.85 5,977.22
PS-GNPs alone 244.67 386.18 1,215.09 2,115.86 3,434.48 4,758.79 5,036.23 6,027.88
2,151.49 2,482.10 3,529.44 3,710.33 4,863.50
Fig. 1 – Photographs displaying tumor masses excised from
right ﬂanks of mice. Tumor masses of saline alone,
PS-GNPs alone, and PS-GNPs plus irradiationgroup were
excised from right ﬂanks of mice on 32nd day aﬁer
injection of Huh7 cells. They are all similar in texture and
color. The ruler is given to estimate the size. PS-GNPs,PS-GNPs + irradiation 134.57 267.75 1,046.29
GNPs, gold nanoparticles; PS, photosensitizer.
treatment other than saline injection (saline alone group)
whereas the other group received only injection of PS-GNPs
solution without photoirradiation (PS-GNPs alone group).
2.4.2. Drug administration and light exposure
Size of tumor was measured every 4 days after establish-
ment of xenograft. Synthesized PS-GNPswere dissolved in PBS
(0.1mg/mL) 24hours before irradiationandkeptdark in analu-
minum foil. PS-GNPs (0.03mg/kg) were directly injected into
the mass of cancer cells by using a Hamilton syringe when
the mass size reached 100mm3. Mice were kept at dark room
for 24hours and an LED (wavelength: 640-710nm) was used
to irradiate the mass of cancer cells. These procedures were
repeated after 16 days of observation with increased amount
of PS-GNPs (0.07mg/kg).
2.4.3. Measurement of tumor size
The efﬁcacy of photodynamic therapy was evaluated by mea-
surement of tumor mass using a digital caliper. The tumor
volume was determined by measuring the length (l) and the
width (w). Tumor size was recorded every 4 days. The mice
were killed after tumor formation, and the tumor samples
were analyzed by the In Situ Apoptosis TUNEL system (Mili-
pore, USA) and by Western blot analysis for speciﬁc cleavage
of caspase-3 (Cell Signaling Technology, USA).
2.4.4. Western blot and TUNEL assay
In order to quantify proteins related with apoptosis, the West-
ern blot was carried out. Tumors were lysed in lysis buffer A
[20mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid
(pH 7.5), 150mM NaCl, 1mM ethylenediaminetetraacetic acid,
2mM ethylene glycol tetraacetic acid, 1% Triton X-100, 10%
glycerol and protease cocktail I/II (Sigma)], and debris was
removed by centrifugation at 15,000 rpm for 10min. Proteins
were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, transferred onto nitrocellulose membranes,
blocked with 5% skim milk in 0.01M Tris-buffered saline
containing 0.5% Tween 20 and blotted with the appropriate
primary antibodies. Membranes were then incubated with
horseradish peroxidase-conjugated goat anti-rabbit-IgG or
goat anti-mouse IgG secondary antibodies for 1hour at room
temperature and detected by chemiluminescence (Abclon,
Korea). The Multi gauge software was used to quantify the
results of Western blot6. TUNEL assay was employed to quan-
tify the degree of apoptosis in tumor mass. The tumors
were removed and frozen in OCT embedding medium, and
then a series of tissue sections (10m in thickness) was
obtained in cryostat (Leica). The sections were incubated in
50L of terminal deoxynuclotidyl transferase-mediate uridine
5’-triphosphate-biotin nick-end labeling (TUNEL) reactionphotosensitizer gold nanoparticles.
mixture (Milipore, USA) for 60min at 37 ◦C, washed and subse-
quently counterstained with 4’, 6’-diamidino-2-phenylindole
(DAPI, 1g/ml, Sigma) for 30min. The sections were mounted
using the Vectashield mounting medium and examined using
a LSM700 confocal laser-scanning microscope (Carl Zeiss,
Germany).
2.4.5. Statistical analysis
Data were analyzed using either the student’s t-test or F-test,
and Sigma-Stat software; the p value was derived to assess the
statistical signiﬁcance and is indicated as *p<0.05; **p<0.01
(Fig. 2).
3. Results
3.1. Change in size of tumor and survival rate of mice
Size of tumor was quantiﬁed by measurement of length (l) and
width (w) using a digital caliper. The volume was calculated
as follows:
Volume (mm3) = lw2/2where L is length (in mm), and w is width of mass. Measure-
ments were carried out twice until the growing volume of
mass reaches 100mm3. Thereafter photodynamic therapy
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Fig. 2 – Change in tumor volume (mm3) during 28 days
after ﬁrst measurement of tumor mass. The growth of
tumor was signiﬁcantly lower (p<0.05) in PS-GNPs plus
irradiation group from 4 days after ﬁrst irradiation
compared with those of the other two groups. First and
second irradiations were indicated by arrows. *p<0.05,
†p<0.01. PS-GNPs, photosensitizer gold nanoparticles.










Fig. 5 – Relative amount of cleaved caspase-3 in PS-GNPs
plus irradiation group compared to saline alone or PS-GNPs
alone group. Protein amount in saline alone group was set
to 1.00 while those of PS-GNPs alone and PS-GNPs plus
irradiation group were expressed as relative values.
signiﬁcantly different between PS-GNPs plus irradiation group
F
e
uompared. PS-GNPs, photosensitizer gold nanoparticles.
egan. The PS-GNPs were injected into the tumor mass
nd the Biospec LED (wavelength: 640-710nm) was used to
rradiate it for 30min after 24hours. There was no signiﬁcant
ize difference among 3 groups until 8-days before irradiation
Table 1 and Figs. 1 and 2). Volume of mass was still rapidly
rowing in all 3 groups on the day of irradiation. On the 4th day
fter ﬁrst irradiation, the volume of mass in the PS-GNPs plus
rradiation group was signiﬁcantly smaller than those in two
ig. 4 – Western blot analysis of activated caspase-3 quantifying
ach group. Procaspase-3 cleavage into p17 and p19 activated ca
sed as a loading control. PS-GNPs, photosensitizer gold nanopa*p<0.05. PS-GNPs, photosensitizer gold nanoparticles.
other groups (saline alone or PS-GNPs alone group). Second
irradiationwas given tomice on 16th day after ﬁrst irradiation.
Themean volume of PS-GNPs plus irradiation groupwas again
signiﬁcantly smaller than those of other groups (4863.50mm3
vs 6027.88, 5977.22mm3) indicating that the photodynamic
therapy is effective in slowing down the rate of tumor growth.
Survival rate was also different among them (Fig. 3). On 20th
day after ﬁrst irradiation, there were 4 mice alive in PS-GNPs
plus irradiation group whereas 3 and 2 mice were alive in
saline alone and PS-GNPs alone group, respectively.
3.2. Cleavage of caspase-3 triggered by PS-GNPs and
irradiation
Theprocaspase-3 cleavage into p17 andp19 activated caspase-
3 and appears as dual band. The activated caspase-3 is
generally used for marker of apoptosis since it is involved
in the progress of cellular apoptosis by destroying DNA. The
cleaved form of caspase-3 was higher in PS-GNPs plus irradi-
ation group than saline alone or PS-GNPs alone group. The
latter two groups were similar in the relative amount of
cleaved caspase-3 (Fig. 4). The tubulin, used for loading con-
trol, was not signiﬁcantly different among those groups.When
the amount of P17, p19 cleaved caspase-3 (QL/area) was nor-
malized to the amount of tubulin (QL/area), the ratio wasand saline alone or PS-GNPs alone group as shown in Fig. 5
indicating that the photodynamic therapy is indeed effective
in triggering apoptosis of cells in hepatocellular carcinoma.
the degree of apoptosis arising from the tumor mass in
spase-3 which subsequently destroy DNAs. -tubulin was
rticles.
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Fig. 6 – Photographs showing TUNEL staining of tumor samples from mice in each group. TUNEL(+) cells were detected
ith oprominently in PS-GNPs plus irradiation group compared w
3.3. DNA fragmentation by PS-GNPs and irradiation
TUNEL assay is a common technique to detect DNA fragmen-
tationwhich results fromapoptotic signaling cascades. TUNEL
immunohistochemistry of hepatic cells in tumor revealed a
distinctive pattern of nuclear staining (Fig. 6). The number of
TUNEL positive cells was signiﬁcantly higher in the PS-GNPs
plus irradiation group compared to the saline aloneor PS-GNPs
alone group (Fig. 6, p<0.01).
4. Discussion
We performed a xenograft protocol to establish an animal
model of hepatocellular carcinoma using Huh7 cells. We
previously conﬁrmed that the xenografts inoculated onto the
right ﬂanks of nude mice retained the genomic characteristics
of hepatocellular carcinoma7. Having identiﬁed growing mass
of hepatocellular carcinoma, we performed PDT twice and
examined its efﬁcacy in treatment of cancer by comparing vol-
ume of tumor mass among groups, counting alive individuals
in each group, carrying out Western blot and TUNEL assay to
quantify apoptosis-related proteins and degree of DNA frag-
mentation, respectively. All the results support the idea that
the PDT using PS-GNPs may be effective in slowing down the
progress of hepatocellular carcinoma. Application of PS-GNPs
alone failed to inhibit the growth of tumor compared with no
treatment. There was no evidence of cytotoxicity by PDT in
normal tissue of mice. The photosensitizing agent, PS-GNPs,
has several distinctive advantages over other PSs. First of
all, it could be sensitized by relatively long light wavelength
which can penetrate into deep tissues. In PDT, wavelengths
shorter than 650nm usually do not allow penetration into
deep tissues but cause unwanted photosensitive reactions.
Too long wavelengths (>850nm) are not able to generate
singlet oxygen which is a key molecule triggering production
of ROS to destroy cancer cells. The range of wavelengths
allowing deep penetration and ensuring therapeutic potential
is called the “phototherapeutic window”.8 The PS-GNPs
used in our experiment is therefore suitable for treatment of
deep-seated tumor mass since its photosensitive wavelengths
lie in the “phototherapeutic window”. In order to selectively
destroy tumors without affecting normal tissues, the ideal PS
should preferentially accumulate in tumor mass. The GNPsther groups. PS-GNPs, photosensitizer gold nanoparticles.
conjugate, one of which we employed as a carrier molecule,
is so far most effective in delivery of PSs in that it allows
PSs being used in photothermal therapy as well as acquiring
enhanced permeability and retention in tumor mass.9,10 The
GNPs conjugate also makes PSs amphipathic resulting in
better cellular uptake and solubility in aqueous phase.
The interval between injection of PSs and irradiation of a
laser affects the outcome of PDT.11 PSs are initially localized to
the vasculature of tumormass after injection. If the irradiation
is given to a tumormass shortly after injectionof a PS, the ther-
apeutic effect is probablymediated by destroying blood supply
to the tumormass. If the PSs are allowed to perfuse into vascu-
lature of tumor mass more than a couple of hours, they would
probably begin to diffuse into most of compartments of tumor
mass including intracellular compartment. Delayed irradia-
tion after injection of PSs is therefore considered to directly
destroy tumor cells rather than shut down blood supply to
them. We employed a longer drug-injection interval (24hours)
to achieve maximal uptake of a PS into tumor mass. Although
the longer interval of drug-injection is thought to be ideal for
complete regression of tumor, it also has a potential danger
to destroy normal tissues as well. The therapeutic response
of the tumor mass in our experiment was at best inhibition
of tumor growth rather than complete regression in spite of
employing the longer drug-injection interval. Apossible expla-
nation for this is that PDT alone is not sufﬁcient for regression
of tumor mass or that hepatocellular carcinoma is relatively
resistant to PDT. A combination therapy such as PDT after
surgical excision might be a solution.
The efﬁcacy of PDT on hepatocellular carcinoma has been
demonstrated by several investigators.12–19 Among them,
Shao et al. (2012) used metal phthalocyanines, a new class
of PSs developed for cancer treatment.19 They used cell lines
in vitro to test efﬁcacy of PDT rather than using a xenograft
protocol. They concluded that the phthalocyanines can
induce apoptosis of cancer cells via reducing mitochondrial
membrane potential, producing ROS, activating caspase-
3, and causing cell arrest at G2/M stage after localizing
into mitochondria and lysosome. The efﬁcacy of PDT on
hepatocellular carcinoma in vivo, however, was rarely tried
without assessment on tumor growth or survival.14 We
believe that the efﬁcacy of PDT on hepatocellular carcinoma
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So far, three different mechanisms are proposed how PDT
auses cell death of cancer cells.20 They are direct cell dam-
ge, vascular shut down, and activation of immune response.
mong them, direct cell damage related with mitochondria is
elieved to be the major cell death modality in cells respond-
ng to PDT. Irradiation of cancer cells highly loaded with PSs
n the appropriate wavelengths range results in production
f ROS which can subsequently damage mitochondrial mem-
rane to release cytochrome C into cytosol. In the cytosol,
ytochrome C binds to apoptotic protease activating factor-1
Apaf-1) andATP,which in turnbinds toprocaspase-9 resulting
n formation of apoptosome.21 The apoptosome then triggers
aspase cascades to cleave nuclear lamins and causes DNA
ragmentation.22 Our results are in accordance with this cell
eath mechanism in that there was a signiﬁcant increase
n caspase-3 (in Western blot) as well as DNA fragmentation
TUNEL assay).
Although we proved that our PDT using a newly developed
S is effective in slowing down the growth of tumor and
mproving survival rate of mice, there are several limitations
n our study. For example, the tumor mass we made was
ocated subcutaneously which is not the real clinical situation
n hepatocellular carcinoma. Irradiation onto deep-seated
rgan might not be sufﬁcient to expect the same degree of
herapeutic effect as in our particular experimental con-
ition. Furthermore, there is no evidence that our PDT is
ore proﬁtable than conventional treatment such as surgical
xcision or chemotherapy in inhibiting tumor growth and
reventing adverse effects. The alternative mechanism, for
xample, impairment of Bcl-2 by PDT-induced oxidation
as not addressed, either. In addition, the most effective
ombination of PDT should be investigated. In spite of those
ssues, the efﬁcacy of our PDT on hepatocellular carcinoma
s quite convincing and the absence of side effects ensures
s it is one of very promising therapeutic modalities against
epatocellular carcinoma.
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